Cancer Harboring BRAF Alterations clinical trials at UCSF

1 research study open to eligible people

Cancer harboring BRAF alterations means the cancer cells have changes in the BRAF gene. UCSF is studying how well a drug called FORE8394 works and how safe it is for people with these changes. The trial looks at how the drug affects the cancer and any side effects.

Showing trials for

  • FORE8394 in Participants with Cancer Harboring BRAF Alterations

    open to eligible people ages 10 years and up

    The objective of this study is to evaluate the efficacy of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare solid tumors, melanoma, thyroid, or recurrent primary CNS tumors harboring BRAF V600E mutation. This will be conducted as four open-label subprotocols (F8394-201A; F8394-201B; F8394-201C; F8394-201D) under one master protocol.

    San Francisco, California and other locations

Last updated: